Picture loading failed.

Adeno Associated Virus (AAV)

AAV Production Protocol--Genemedi


1. AAV plasmid construction

The gene of interest is cloned into one of the ITR/MCS-containing AAV vectors to generate AAV-GOI. The purity and RNAse contaminants of AAV viral plasmid should be taken into consideration.

2. AAV packaging

The recombinant AAV viral plasmid AAV-GOI is co-transfected into the AAV-293 cells with AAV helper plasmid pHelper (carrying adenovirus-derived genes) and AAV-RC (carrying AAV-2 replication and capsid genes), which together supply all the trans-acting factors required for AAV replication and packaging in the AAV-293 cells.

3. Harvesting AAV particles

Collecting the cells and freeze/thaw the cell pellet to release the AAV virus.

4. AAV purification

Purify the AAV virus with gradient ultracentrifugation to separate contaminants from the impure AAV preparations.

5.AAV titer detection

Determine AAV titer by real-time quantitative PCR (QPCR) using primers targeting the AAV ITR. Titer values are then identified by comparison to a standard curve of a plasmid sample of known concentration.

6.Quality control of AAV

After AAV virus titer detection, the infection activity needs to be evaluated before animal experiments by infecting cells such as 293T, CHO to test the gene expression. MOI for AAV mediated gene transduction in cells will be controlled ranging from 10^4 to 10^5.


Adeno-associated virus (AAV vector) - Guidelines

pdf downloadNIH Guidelines for Adeno-Associated (AAV) Lentivirus and Adenovirus pdf downloadGuidance for Gene Therapy Clinical trials-FDA
pdf downloadHuman Gene Therapy For Rare Diseases pdf downloadHuman Gene Therapy for Retinal Disorders
pdf downloadHuman Gene Therapy for Hemophilia


View Adeno-associated virus (AAV vector) Knowledge Base>>

Other knowledge bases

AAV Knowledge Basepdf download
CRISPR/Cas9-gRNA system Knowledge Base
Adenovirus Knowledge Basepdf download
Transfection Knowledge Base
Lentivirus Knowledge Basepdf download
Advanced cell therapy